Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer

Objective： To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer （NSCLC）. Methods： A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity. Results： A total of 89 patients were assessable. In patients treated with icotinib, the overall response rate （RR） was 36.0% （32/89）, and the disease control rate （DCR） was 69.7% （62/89）. RR and DCR were significantly improved in patients with adenocarcinoma versus non-adenocarcinoma （P〈0.05）. The symptom improvement rate was 57.3% （51/89）, and the main symptoms improved were cough, pain, chest distress, dyspnea, and Eastern Cooperative Oncology Group performance status. The main toxic effects were rash [30/89 （33.7%）] and diarrhea [15/89 （16.9%）]. The level of toxicity was typically low. Conclusions： The use of icofinib hydrochloride in the treatment of advanced NSCLC is efficacious and safe, and its toxic effects are tolerable.

P53、C-erbB-2和VEGF在非小细胞肺癌中的表达及其临床意义(英文)

Objective: To investigate the expressions and the clinical significance of P53, C-erbB-2 and vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC). Methods: 121 specimens of NSCLC were examined for P53, C-erbB-2 and VEGF by immunohistochemical staining. Results: The positive rates of P53, C-erbB-2 and VEGF in the carci- nomatous tissue were 43%, 39% and 31% respectively. P53 gene protein expression in lung cancer was significantly related to histological type and P-TNM staging of lung cancer patients (P < 0.05), and was not associated with the sex, age, the size of primary cancer, lymph node metastasis and cell differentiation (P > 0.05). C-erbB-2 gene protein expression in lung cancer was closely related to histological type and cell differentiation (P < 0.05), and was not associated with the sex, age, the size of primary cancer, lymph node metastasis and P-TNM staging of lung cancer patients (P > 0.05). VEGF in lung cancer was only closely related to cell differentiation (P < 0.05), and was not associated with the sex, age, the size of primary cancer, lymph node metastasis, histological type and P-TNM staging of lung cancer patients (P > 0.05). Conclusion: It is possible for P53, C-erbB-2 and VEGF to play an important role in the oncogenesis and development of non-small cell lung cancer.

The Infection of Healthcare Workers and the Reinfection of Patients by Omicron Variant—Jiangsu Province,China,December 2022 to January 2023

Summary What is already known about this topic?Healthcare workers(HCWs)and previously infected patients(PIPs)may experience a wave of epidemic following the modification of the country’s coronavirus disease(COVID)-zero policy in China.What is added by this report?As of early January 2023,the initial wave of the COVID-19 pandemic among HCWs had effectively subsided,with no statistically significant differences observed in infection rates compared to those of their co-occupants.The proportion of reinfections among PIPs was relatively low,particularly in those with recent infections.What are the implications for public health practice?Medical and health services have resumed normal operations.For patients who have recently experienced severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infections,appropriate relaxation of policies may be considered.